Phytomedicine : international journal of phytotherapy and phytopharmacology
Cure8 research brief
Why This Matters
The study links a common dietary flavonoid, epicatechin, to restoration of a protective ILC3 subset and mucosal repair in mouse colitis via a defined molecular pathway. This could point to new therapeutic targets for ulcerative colitis in the future.
Who Should Pay Attention
Researchers in immunology and IBD drug discovery; clinicians following translational IBD research; patients curious about preclinical work on dietary compounds and mucosal healing.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study (abstract) reports that epicatechin, a dietary flavonoid, reduced inflammation and improved mucosal repair in a mouse model of acute DSS-induced colitis and in ILC3-derived cells in vitro.
The researchers found epicatechin increased NCR+ ILC3 numbers and IL-22 expression, linked to activation of a NLE1–NICD–HIF-1α signaling pathway; NLE1 was identified as a direct molecular target using proteomic and knockdown experiments.
The work combined mouse DSS colitis experiments, cell-line (MNK3) assays, flow cytometry, histology, barrier-protein measurements, and biochemical target identification (DARTS, CETSA, mass spectrometry, co-IP). Knockdown of NLE1 blocked the effects, supporting a mechanistic role.
This is preclinical, mechanistic research in mice and cells, not a human clinical trial or approved therapy. It suggests epicatechin or NLE1-related pathways as potential leads for mucosal repair, but does not establish safety, dosing, or efficacy in people.
Keep In Mind
Preclinical mouse and cell-line study; not evidence of human benefit or safety. Further research and clinical trials would be needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPhytomedicine : international journal of phytotherapy and phytopharmacology
AuthorsXu R, Yi Q, Chen H +9 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Chishizhi Yuyuliang Decoction Ameliorates Ulcerative Colitis in Mice by Promoting Colonic Epithelial Mucosal Healing via the CAV1/FA Axis.
This paper identifies a herbal formula that improved inflammation and epithelial barrier repair in a mouse colitis model and highlights specific molecular pathways (CAV1/FAK/paxillin and metabolite pathways) that might...
Mycobacterium tuberculosis PPE2 protein-derived peptide ameliorates DSS-induced colitis by depleting mast cells
This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...
Benzoylpaeoniflorin regulates macrophage polarization via the RNF31-DPEP2 axis to ameliorate intestinal mucosal barrier damage in ulcerative colitis.
This preclinical study identifies benzoylpaeoniflorin (BPF) as a compound that improved experimental colitis in mice by changing macrophage polarization via the RNF31–DPEP2–NF-κB pathway. It highlights a possible...